Vertex Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Vertex Pharmaceuticals
VRTX Stock  USD 468.13  3.57  0.77%   
Vertex Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Vertex Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vertex Pharmaceuticals financial statements helps investors assess Vertex Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vertex Pharmaceuticals' valuation are summarized below:
Gross Profit
5.3 B
Profit Margin
(0.05)
Market Capitalization
120.6 B
Enterprise Value Revenue
10.8054
Revenue
10.6 B
We have found one hundred twenty available fundamental trend indicators for Vertex Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vertex Pharmaceuticals current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 8.4 B in 2024. Enterprise Value is likely to drop to about 8.3 B in 2024

Vertex Pharmaceuticals Total Revenue

10.36 Billion

Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Vertex Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets23.9 B22.7 B8.2 B
Slightly volatile
Short and Long Term Debt Total848.8 M808.4 M632.1 M
Slightly volatile
Total Current Liabilities3.7 B3.5 B1.2 B
Slightly volatile
Total Stockholder Equity18.5 B17.6 B5.9 B
Slightly volatile
Property Plant And Equipment Net1.5 B1.5 B791.1 M
Slightly volatile
Cash10.9 B10.4 B3.7 B
Slightly volatile
Non Current Assets Total9 B8.6 B3 B
Slightly volatile
Non Currrent Assets Other836.5 M796.7 M368.3 M
Slightly volatile
Cash And Short Term Investments11.8 B11.2 B4.3 B
Slightly volatile
Common Stock Shares Outstanding153.1 M260.5 M223.3 M
Slightly volatile
Liabilities And Stockholders Equity23.9 B22.7 B8.2 B
Slightly volatile
Non Current Liabilities Total1.7 B1.6 B1.3 B
Slightly volatile
Other Current Assets654.9 M623.7 M277.1 M
Slightly volatile
Other Stockholder Equity7.8 B7.4 B6.2 B
Slightly volatile
Total Liabilities5.4 B5.1 B2.3 B
Slightly volatile
Total Current Assets14.9 B14.1 B5.2 B
Slightly volatile
Accounts Payable383.1 M364.9 M140.6 M
Slightly volatile
Property Plant And Equipment Gross2.8 B2.6 B1.1 B
Slightly volatile
Net Receivables1.6 B1.6 B590.9 M
Slightly volatile
Common Stock Total Equity1.9 M3 M2.3 M
Slightly volatile
Common Stock2 M3 M2.3 M
Slightly volatile
Other Assets1.7 B1.6 B618.2 M
Slightly volatile
Long Term Debt446.2 M646.2 M554.3 M
Pretty Stable
Short Term Investments579.6 M849.2 M558.1 M
Pretty Stable
Property Plant Equipment1.8 B1.7 B851.9 M
Slightly volatile
Other Liabilities828.1 M788.7 M365.2 M
Slightly volatile
Current Deferred Revenue118.8 M170.3 M135.4 M
Slightly volatile
Inventory775.7 M738.8 M222.7 M
Slightly volatile
Good Will1.3 B1.3 B548 M
Slightly volatile
Intangible Assets424.7 M839.9 M379.8 M
Pretty Stable
Long Term Debt Total632.6 M619.9 M577.1 M
Pretty Stable
Capital Surpluse6.9 B8.5 B6.4 B
Slightly volatile
Deferred Long Term Liabilities6.9 M7.3 M98.3 M
Slightly volatile
Non Current Liabilities Other186.5 M196.3 M358.1 M
Slightly volatile
Capital Lease Obligations848.8 M808.4 M270.5 M
Slightly volatile
Short and Long Term Debt732.3 M697.4 M367.4 M
Slightly volatile
Long Term Investments2.6 B2.5 B383.5 M
Slightly volatile
Net Invested Capital9.9 B17.6 B5.8 B
Slightly volatile
Net Working Capital6.6 B10.6 B4.1 B
Slightly volatile
Capital Stock2.8 M3 M2.6 M
Slightly volatile

Vertex Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue10.4 B9.9 B4 B
Slightly volatile
Gross Profit9 B8.6 B3.5 B
Slightly volatile
Other Operating Expenses6.3 B6 B2.7 B
Slightly volatile
Total Operating Expenses5 B4.8 B2.2 B
Slightly volatile
Depreciation And Amortization190.4 M181.3 M97.3 M
Slightly volatile
Research Development3.3 B3.2 B1.6 B
Slightly volatile
Selling General Administrative1.2 B1.1 B590.8 M
Slightly volatile
Extraordinary Items1.9 B1.8 B1.5 B
Slightly volatile
Non Recurring102.7 M104 M122.4 M
Very volatile
Interest Income645.4 M614.7 M144.9 M
Slightly volatile
Reconciled Depreciation126.6 M181.3 M90.8 M
Slightly volatile

Vertex Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow11 B10.5 B3.1 B
Slightly volatile
Depreciation190.4 M181.3 M87.1 M
Slightly volatile
Capital Expenditures271.3 M258.4 M135.4 M
Slightly volatile
End Period Cash Flow10.9 B10.4 B3.7 B
Slightly volatile
Stock Based Compensation610.3 M581.2 M303.1 M
Slightly volatile
Change To Netincome437.4 M512.4 M407.9 M
Slightly volatile
Issuance Of Capital Stock347.9 M394.7 M314.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.0910.624515.1051
Slightly volatile
PTB Ratio7.465.964311.7428
Slightly volatile
Days Sales Outstanding58.2857.820449.5933
Slightly volatile
Book Value Per Share71.6368.220423.1877
Slightly volatile
Stock Based Compensation To Revenue0.05590.05890.1037
Pretty Stable
Capex To Depreciation1.11.42531.5432
Very volatile
PB Ratio7.465.964311.7428
Slightly volatile
EV To Sales9.179.655814.6552
Slightly volatile
Inventory Turnover1.621.70843.4595
Slightly volatile
Days Of Inventory On Hand111214151
Very volatile
Sales General And Administrative To Revenue0.260.210.2658
Slightly volatile
Research And Ddevelopement To Revenue0.30.32050.6494
Slightly volatile
Capex To Revenue0.02490.02620.0665
Slightly volatile
Cash Per Share45.7143.532417.0521
Slightly volatile
Intangibles To Total Assets0.150.08480.1259
Slightly volatile
Current Ratio3.793.987218.3538
Very volatile
Tangible Book Value Per Share63.7860.739219.9468
Slightly volatile
Receivables Turnover8.776.31277.9952
Slightly volatile
Graham Number15414753.0273
Slightly volatile
Shareholders Equity Per Share71.6368.220423.0556
Slightly volatile
Capex Per Share1.051.00270.5481
Slightly volatile
Revenue Per Share40.2138.297215.8837
Slightly volatile
Operating Cycle285271204
Pretty Stable
Price Book Value Ratio7.465.964311.7428
Slightly volatile
Company Equity Multiplier1.81.29291.8142
Slightly volatile
Long Term Debt To Capitalization0.03380.03560.1242
Slightly volatile
Quick Ratio3.593.778917.5799
Very volatile
Cash Ratio5.82.92312.4464
Very volatile
Days Of Inventory Outstanding111214151
Very volatile
Days Of Sales Outstanding58.2857.820449.5933
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.50.92691.021
Very volatile
Price To Book Ratio7.465.964311.7428
Slightly volatile
Fixed Asset Turnover7.136.79284.5982
Slightly volatile
Price Sales Ratio10.0910.624515.1051
Slightly volatile
Asset Turnover0.250.43420.4783
Very volatile
Gross Profit Margin1.090.87210.9394
Slightly volatile
Price Fair Value7.465.964311.7428
Slightly volatile

Vertex Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8.4 B16.2 B17.2 B
Very volatile
Enterprise Value8.3 B15.8 B17 B
Very volatile

Vertex Fundamental Market Drivers

Forward Price Earnings25.2525
Cash And Short Term Investments11.2 B

Vertex Upcoming Events

5th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue170.3 M118.8 M
Total Revenue9.9 B10.4 B
Cost Of Revenue1.3 B1.3 B
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 0.21  0.26 
Research And Ddevelopement To Revenue 0.32  0.30 
Capex To Revenue 0.03  0.02 
Revenue Per Share 38.30  40.21 
Ebit Per Revenue 0.44  0.46 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY